个体参与者数据荟萃分析（IPDMA）：数据贡献与试验对应作者的国家、发表年份和期刊影响因子有关。

Individual participant data meta-analyses (IPDMA): data contribution was associated with trial corresponding author country, publication year, and journal impact factor.

机构信息

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada.

出版信息

J Clin Epidemiol. 2020 Aug;124:16-23. doi: 10.1016/j.jclinepi.2020.03.026. Epub 2020 Apr 13.

DOI:10.1016/j.jclinepi.2020.03.026

PMID:32298776

Abstract

OBJECTIVES

The objectives were to determine the proportion of eligible randomized controlled trials (RCTs) that contributed data to individual participant data meta-analyses (IPDMAs) and explore associated factors.

STUDY DESIGN AND SETTING

IPDMAs with ≥10 eligible RCTs were identified by searching MEDLINE, EMBASE, CINAHL, and Cochrane May 1, 2015 to February 13, 2017. Mixed-effect logistic regression was used to identify factors associated with data contribution.

RESULTS

Of 774 eligible RCTs from 35 included IPDMAs, 517 (67%, 95% confidence interval [CI]: 63%-70%) contributed data. Compared to RCTs from journals with low-impact factors (0-2.4), RCTs from journals with higher impact factors were more likely to contribute data: impact factor 5.0-9.9, odds ratio [OR] 2.6, 95% CI: 1.37-4.86; impact factor: 10.0-19.9, OR: 5.7, 95% CI: 3.0-10.8; impact factor >20.0, OR: 4.6, 95% CI: 1.9-11.4. RCTs from the United Kingdom were more likely to contribute data than those from the United States (reference; OR: 2.4, 95% CI, 1.3-4.6). There was an increase in OR per publication year (OR: 1.05, 95% CI: 1.02-1.09).

CONCLUSION

The country where RCTs are conducted, impact factor of the journal where RCTs are published, and RCT publication year were associated with data contribution in IPDMAs with ≥10 eligible RCTs.

摘要

目的

本研究旨在确定纳入个体参与者数据荟萃分析（IPDMA）的合格随机对照试验（RCT）的比例，并探讨其相关因素。

研究设计与设置

通过检索 MEDLINE、EMBASE、CINAHL 和 Cochrane 数据库，于 2015 年 5 月 1 日至 2017 年 2 月 13 日，确定了纳入≥10 项合格 RCT 的 IPDMA。采用混合效应逻辑回归分析确定与数据贡献相关的因素。

结果

在纳入的 35 项 IPDMA 中，有 774 项合格 RCT，其中 517 项（67%，95%置信区间[CI]：63%-70%）提供了数据。与影响因子低（0-2.4）的期刊相比，影响因子高（5.0-9.9、10.0-19.9、>20.0）的期刊中的 RCT 更有可能提供数据：影响因子 5.0-9.9 的 RCT 的比值比（OR）为 2.6，95%CI：1.37-4.86；影响因子 10.0-19.9 的 RCT 的 OR 为 5.7，95%CI：3.0-10.8；影响因子>20.0 的 RCT 的 OR 为 4.6，95%CI：1.9-11.4。与来自美国的 RCT 相比，来自英国的 RCT 更有可能提供数据（OR：2.4，95%CI：1.3-4.6）。OR 随每年发表的 RCT 数量而增加（OR：1.05，95%CI：1.02-1.09）。